Gregory A Otterson
Overview
Explore the profile of Gregory A Otterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
11639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greib A, Zhao S, Ploch M, Henricks J, Easterling R, Moodabagil M, et al.
Oncoimmunology
. 2025 Feb;
14(1):2469375.
PMID: 39981683
Immune checkpoint inhibitors (ICIs) are first line treatment for advanced lung cancer. Tobacco use is a shared risk factor for lung cancer and chronic obstructive pulmonary disease (COPD). Although many...
2.
Stevenson J, Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 Mar;
22(2):72-81.
PMID: 38503043
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States...
3.
Riely G, Smit E, Ahn M, Felip E, Ramalingam S, Tsao A, et al.
Future Oncol
. 2024 Feb;
20(16):1047-1055.
PMID: 38357801
What Is This Summary About?: This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI) and binimetinib (MEKTOVI). This...
4.
Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang J, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1164-1171.e5.
PMID: 37935100
Background: Immune checkpoint inhibitors (ICIs) are a first-line and perioperative treatment for lung cancer. Pneumonitis is a potentially life-threatening complication of ICI treatment in 2% to 5% of patients; however,...
5.
Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2023 Sep;
21(9):961-979.
PMID: 37673108
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM)....
6.
Riely G, Smit E, Ahn M, Felip E, Ramalingam S, Tsao A, et al.
J Clin Oncol
. 2023 Jun;
41(21):3700-3711.
PMID: 37270692
Purpose: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with -mutant metastatic melanoma. We evaluated the efficacy...
7.
Johns A, Yang M, Wei L, Grogan M, Spakowicz D, Patel S, et al.
Oncologist
. 2023 Apr;
28(8):e625-e632.
PMID: 37085156
Objectives: Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically...
8.
Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A, et al.
J Natl Compr Canc Netw
. 2023 Apr;
21(4):340-350.
PMID: 37015337
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known...
9.
Shaker N, Amadi C, Welliver M, Otterson G, Liebner D, Shilo K
Int J Surg Pathol
. 2023 Apr;
31(8):1598-1604.
PMID: 37013353
Carcinosarcomas of mediastinum are rare and only few well-documented cases are available in the literature. We report a detailed description of mediastinal carcinosarcoma with unique clinical manifestations and immunohistochemical and...
10.
Villaruz L, Blumenschein Jr G, Otterson G, Leal T
Cancer
. 2023 Feb;
129(9):1319-1350.
PMID: 36848319
The availability of agents targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has transformed treatment of advanced and/or metastatic non-small cell lung cancer (NSCLC). However,...